Skip to content

An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer

An Initial Feasibility Study to Integrate High-precision, Image Guided, Radiotherapy(MRI Based Brachytherapy and CT/MRI Fused Dynamic IMRT Planning) in the Treatment Planning of 10 Patients With Locally Advanced Carcinoma of the Cervix

Status
Withdrawn
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01514955
Acronym
IMRT
Enrollment
0
Registered
2012-01-23
Start date
2009-11-30
Completion date
2011-12-31
Last updated
2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Integrated MRI Based RT as Standard of Care, Locally Advanced Cervical Cancer

Brief summary

Main cause of mortality in cervix cancer is local relapse in the pelvis. Since distant metastasis is quiet rare, increasing local control in the pelvis can directly translate into improvement in survival. Obstacles in front of this approach is the dose limitation to normal organs located in the pelvis adjacent to the tumor. 3-D MRI based EBRT and Brachytherapy will grant safe delivery of more conformal higher doses of radiation to the tumor and allowing sparing of the normal structures.

Detailed description

A total of 10 patients with a diagnosis of locally advanced cervical carcinoma will be enrolled. After diagnosis and written informed consent, patients will undergo investigations prior to treatment planning, including CT imaging as per standard of care. In addition, patients will have an MRI of the pelvis + PET scan + EUA and gold seeds insertion to verify pelvic organs movement and EB-IMRT with daily cone beam CT. Brachytherapy treatment planning will be based on MRI imaging with the applicator in situ.

Interventions

RADIATIONGold seeds insertion to detect movements at pelvis
RADIATIONImage guided MRI based RT (IMRT+Brachytherapy)

Sponsors

Cross Cancer Institute
CollaboratorOTHER
AHS Cancer Control Alberta
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-chemo-therapy including MRI guided BT. (stage IB2 bulky disease-stage IVa) * Staging according to FIGO and TNM guidelines * Positive biopsy showing squamous cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix * No pelvic nodes \> 2cm * MRI of pelvis at diagnosis * MRI of the retroperitoneal space and abdomen at diagnosis * MRI with applicator in place at time of BT * Age 18-70 years * Patient informed consent

Exclusion criteria

* Pelvic nodes \> 2cm * Previous pelvic or abdominal radiotherapy * Previous total or partial hysterectomy * Combination of preoperative radiotherapy with surgery * Patients receiving neo-adjuvant chemotherapy * Patients receiving BT only * Contraindications to MRI

Design outcomes

Primary

MeasureTime frame
Feasibility parametersOne year

Secondary

MeasureTime frame
Response rate, acute and late toxicity, local control rate, survivalFive years
Dosimetric comparison between 2D and 3D Brachytherapy treatment planning

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026